JILIN AODONG(SZ:000623) Zheng Quan Zhi Xing·2025-08-29 10:24Core Viewpoint - The company has completed all fundraising projects related to the 2018 convertible bonds and plans to permanently supplement its working capital with the remaining funds totaling 200.2361 million yuan [1][10]. Fundraising Overview - The company raised a total of 241.3 million yuan through the issuance of convertible bonds, with 2.44613 million yuan allocated for issuance costs [9]. - The remaining funds after project expenditures and pending payments amount to 200.2361 million yuan, which includes 119.2776 million yuan from the Chinese medicine formula granule project and 80.9585 million yuan from idle funds and interest income [1][9]. Project Completion - The Chinese medicine formula granule project has been completed and is now in a usable state, with a surplus of 119.2776 million yuan [8][9]. - All fundraising projects associated with the 2018 convertible bonds have been concluded as of June 30, 2025 [9]. Financial Management - The company has adhered to strict financial management regulations, ensuring that funds are used efficiently and effectively while maintaining project quality [8]. - The company has utilized some temporarily idle funds for cash management, generating investment income and interest during the fund storage period [8][9]. Decision-Making Process - The decision to conclude the fundraising projects and allocate surplus funds for working capital was approved by the company's board and supervisory committee, aligning with shareholder interests [10][11]. - The supervisory committee and the sponsor institution have expressed their agreement with the decision, confirming compliance with relevant regulations [11][12].